497832-40-3

Upstream product

• 1395892-95-1 C₅₃H₈₂N₂O₁₆ 
• 26116-56-3 erythromycylamine 
• 79617-15-5 [10-(4-dimethylamino-3-hydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-2-ethyl-3,4,9-trihydroxy-12-(5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydro-pyran-2-yloxy)-3,5,7,9,11,13-hexamethyl-14-oxo-oxacyclotetradec-6-yl]-carbamic acid benzyl ester 
• 994-30-9 triethylsilyl chloride 

Downstream Products

• 497832-43-6 C₄₉H₇₇N₅O₁₄ 
• 497832-45-8 C₅₉H₉₅N₅O₁₅ 
• 497832-06-1 C₄₉H₈₇N₅O₁₂ 
• 497832-41-4 C₆₀H₁₁₁N₃O₁₄Si₂ 

Relevant academic research and scientific papers

Synthesis and structure-activity relationship of a novel class of 15-membered macrolide antibiotics known as '11a-azalides'

Macrolide antibiotics are widely prescribed for the treatment of respiratory tract infections; however, the increasing prevalence of macrolide-resistant pathogens is a public health concern. Therefore, the development of new macrolide scaffolds with activities against resistant pathogens is urgently needed. An efficient method for reconstructing the erythromycin A macrolactone skeleton has been established. Based on this methodology, novel 15-membered macrolides, known as '11a-azalides', with substituents at the C12, C13, or C4″ positions were synthesized and their antibacterial activities were evaluated. These derivatives showed promising antibacterial activities against erythromycin-resistant Streptococcus pneumoniae. Among them, the C4″ substituted derivatives had the most potent activity against erythromycin-resistant S. pneumoniae.